Pharmacological inhibition of S6K1 increases glucose metabolism and Akt signalling in vitro and in diet-induced obese mice

Diabetologia

Volumn 59, Issue 3, 2016, Pages 592-603

  Shum, Michael ^a   Bellmann, Kerstin ^a   St Pierre, Philippe ^a   Marette, André ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

Akt; Glucose tolerance; Glucose uptake; Hepatic glucose production; Insulin resistance; mTORC1; PF 4708671; Rapamycin; S6K1; Type 2 diabetes

Indexed keywords

GLUCOSE; PF 4708671; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE INHIBITOR; RAPAMYCIN; S6 KINASE; S6K1 PROTEIN; UNCLASSIFIED DRUG; IMIDAZOLE DERIVATIVE; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; PF-4708671; PIPERAZINE DERIVATIVE; S6K1 PROTEIN, RAT; TARGET OF RAPAMYCIN KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIET INDUCED OBESITY; ENZYME PHOSPHORYLATION; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; GLUCOSE TRANSPORT; IN VITRO STUDY; LIVER CELL; MALE; MOUSE; MYOBLAST; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; CARBOHYDRATE METABOLISM; CELL LINE; DRUG EFFECTS; METABOLISM; MOUSE MUTANT; OBESITY; RAT;

ANIMALS; CARBOHYDRATE METABOLISM; CELL LINE; GLUCOSE; IMIDAZOLES; MICE, OBESE; MULTIPROTEIN COMPLEXES; OBESITY; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RIBOSOMAL PROTEIN S6 KINASES; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84957437544     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-015-3839-6     Document Type: Article

References (48)

1. Draznin B (2006) Molecular mechanisms of insulin resistance: serine phosphorylation of insulin receptor substrate-1 and increased expression of p85alpha: the two sides of a coin. Diabetes 55:2392–2397
2. Gual P, Le Marchand-Brustel Y, Tanti JF (2005) Positive and negative regulation of insulin signaling through IRS-1 phosphorylation. Biochimie 87:99–109
3. Fenton TR, Gout IT (2011) Functions and regulation of the 70kDa ribosomal S6 kinases. Int J Biochem Cell Biol 43:47–59
4. Magnuson B, Ekim B, Fingar DC (2012) Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks. Biochem J 441:1–21
5. Pardo OE, Seckl MJ (2013) S6K2: the neglected S6 kinase family member. Front Oncol 3:191
6. Copps KD, White MF (2012) Regulation of insulin sensitivity by serine/threonine phosphorylation of insulin receptor substrate proteins IRS1 and IRS2. Diabetologia 55:2565–2582
7. Hancer NJ, Qiu W, Cherella C, Li Y, Copps KD, White MF (2014) Insulin and metabolic stress stimulate multisite serine/threonine phosphorylation of insulin receptor substrate 1 and inhibit tyrosine phosphorylation. J Biol Chem 289:12467–12484
8. Shah OJ, Hunter T (2006) Turnover of the active fraction of IRS1 involves raptor-mTOR- and S6K1-dependent serine phosphorylation in cell culture models of tuberous sclerosis. Mol Cell Biol 26:6425–6434
9. Veilleux A, Houde VP, Bellmann K, Marette A (2010) Chronic inhibition of the mTORC1/S6K1 pathway increases insulin-induced PI3K activity but inhibits Akt2 and glucose transport stimulation in 3T3-L1 adipocytes. Mol Endocrinol 24:766–778
10. Tremblay F, Brule S, Hee Um S et al (2007) Identification of IRS-1 Ser-1101 as a target of S6K1 in nutrient- and obesity-induced insulin resistance. Proc Natl Acad Sci U S A 104:14056–14061
11. Liu P, Gan W, Inuzuka H et al (2013) Sin1 phosphorylation impairs mTORC2 complex integrity and inhibits downstream Akt signalling to suppress tumorigenesis. Nat Cell Biol 15:1340–1350
12. Um SH, Frigerio F, Watanabe M et al (2004) Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 431:200–205
13. Pende M, Kozma SC, Jaquet M et al (2000) Hypoinsulinaemia, glucose intolerance and diminished beta-cell size in S6K1-deficient mice. Nature 408:994–997
14. Younis HS, Hirakawa B, Scott W et al (2011) Antisense inhibition of S6 kinase 1 produces improved glucose tolerance and is well tolerated for 4 weeks of treatment in rats. Pharmacology 87:11–23
15. Bae EJ, Xu J, Oh DY et al (2012) Liver-specific p70 S6 kinase depletion protects against hepatic steatosis and systemic insulin resistance. J Biol Chem 287:18769–18780
16. Tremblay F, Marette A (2001) Amino acid and insulin signaling via the mTOR/p70 S6 kinase pathway. A negative feedback mechanism leading to insulin resistance in skeletal muscle cells. J Biol Chem 276:38052–38060
17. Tremblay F, Gagnon A, Veilleux A, Sorisky A, Marette A (2005) Activation of the mammalian target of rapamycin pathway acutely inhibits insulin signaling to Akt and glucose transport in 3T3-L1 and human adipocytes. Endocrinology 146:1328–1337
18. Tzatsos A, Kandror KV (2006) Nutrients suppress phosphatidylinositol 3-kinase/Akt signaling via raptor-dependent mTOR-mediated insulin receptor substrate 1 phosphorylation. Mol Cell Biol 26:63–76
19. Houde VP, Brule S, Festuccia WT et al (2010) Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue. Diabetes 59:1338–1348
20. Deblon N, Bourgoin L, Veyrat-Durebex C et al (2012) Chronic mTOR inhibition by rapamycin induces muscle insulin resistance despite weight loss in rats. Br J Pharmacol 165:2325–2340
21. Pearce LR, Alton GR, Richter DT et al (2010) Characterization of PF-4708671, a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1). Biochem J 431:245–255
22. Bedard S, Marcotte B, Marette A (1997) Cytokines modulate glucose transport in skeletal muscle by inducing the expression of inducible nitric oxide synthase. Biochem J 325(Pt 2):487–493
23. Smadja-Lamere N, Shum M, Deleris P, Roux PP, Abe J, Marette A (2013) Insulin activates RSK (p90 ribosomal S6 kinase) to trigger a new negative feedback loop that regulates insulin signaling for glucose metabolism. J Biol Chem 288:31165–31176
24. Folch J, Lees M, Sloane Stanley GH (1957) A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226:497–509
25. Lo S, Russell JC, Taylor AW (1970) Determination of glycogen in small tissue samples. J Appl Physiol 28:234–236
26. Rosner M, Schipany K, Hengstschlager M (2012) p70 S6K1 nuclear localization depends on its mTOR-mediated phosphorylation at T389, but not on its kinase activity towards S6. Amino Acids 42:2251–2256
27. Vainer GW, Saada A, Kania-Almog J, Amartely A, Bar-Tana J, Hertz R (2014) PF-4708671 activates AMPK independently of p70S6K1 inhibition. PLoS One 9:e107364
28. Fang Y, Westbrook R, Hill C et al (2013) Duration of rapamycin treatment has differential effects on metabolism in mice. Cell Metab 17:456–462
29. Lamming DW, Ye L, Katajisto P et al (2012) Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science 335:1638–1643
30. Johnston O, Rose CL, Webster AC, Gill JS (2008) Sirolimus is associated with new-onset diabetes in kidney transplant recipients. Clin J Am Soc Nephrol 19:1411–1418
31. Laplante M, Sabatini DM (2012) mTOR signaling in growth control and disease. Cell 149:274–293
32. Sarbassov DD, Ali SM, Sengupta S et al (2006) Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 22:159–168
33. Ye L, Varamini B, Lamming DW, Sabatini DM, Baur JA (2012) Rapamycin has a biphasic effect on insulin sensitivity in C2C12 myotubes due to sequential disruption of mTORC1 and mTORC2. Front Genet 3:177
34. Jacinto E, Facchinetti V, Liu D et al (2006) SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 127:125–137
35. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307:1098–1101
36. Liu P, Guo J, Gan W, Wei W (2014) Dual phosphorylation of Sin1 at T86 and T398 negatively regulates mTORC2 complex integrity and activity. Protein Cell 5:171–177
37. Di R, Wu X, Chang Z et al (2012) S6K inhibition renders cardiac protection against myocardial infarction through PDK1 phosphorylation of Akt. Biochem J 441:199–207
38. Mendez-Lucas A, Duarte JA, Sunny NE et al (2013) PEPCK-M expression in mouse liver potentiates, not replaces, PEPCK-C mediated gluconeogenesis. J Hepatol 59:105–113
39. Stark R, Guebre-Egziabher F, Zhao X et al (2014) A role for mitochondrial phosphoenolpyruvate carboxykinase (PEPCK-M) in the regulation of hepatic gluconeogenesis. J Biol Chem 289:7257–7263
40. van Schaftingen E, Gerin I (2002) The glucose-6-phosphatase system. Biochem J 362:513–532
41. Samuel VT, Beddow SA, Iwasaki T et al (2009) Fasting hyperglycemia is not associated with increased expression of PEPCK or G6Pc in patients with type 2 diabetes. Proc Natl Acad Sci U S A 106:12121–12126
42. Foretz M, Hebrard S, Leclerc J et al (2010) Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest 120:2355–2369
43. Pende M, Um SH, Mieulet V et al (2004) S6K1(-/-)/S6K2(-/-) mice exhibit perinatal lethality and rapamycin-sensitive 5'-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway. Mol Cell Biol 24:3112–3124
44. Shima H, Pende M, Chen Y, Fumagalli S, Thomas G, Kozma SC (1998) Disruption of the p70(s6k)/p85(s6k) gene reveals a small mouse phenotype and a new functional S6 kinase. EMBO J 17:6649–6659
45. Taylor KM, Bajko J, Cabrera MS et al (2014) S6 kinase 2 deficiency improves glucose disposal in mice fed a high fat diet. J Diabetes Metab 5:441. doi:10.4172/2155-6156.1000441
46. Ismail HM, Myronova O, Tsuchiya Y, Niewiarowski A, Tsaneva I, Gout I (2013) Identification of the general transcription factor Yin Yang 1 as a novel and specific binding partner for S6 kinase 2. Cell Signal 25:1054–1063
47. Lu Y, Xiong X, Wang X et al (2013) Yin Yang 1 promotes hepatic gluconeogenesis through upregulation of glucocorticoid receptor. Diabetes 62:1064–1073
48. Kim K, Pyo S, Um SH (2012) S6 kinase 2 deficiency enhances ketone body production and increases peroxisome proliferator-activated receptor alpha activity in the liver. Hepatology 55:1727–1737